Budget Options

Budget Options
Author: United States. Congressional Budget Office
Publisher:
Total Pages: 240
Release: 1977
Genre: Budget
ISBN:

Budget and Economic Outlook

Budget and Economic Outlook
Author: Congressional Budget Office
Publisher: Government Printing Office
Total Pages: 184
Release: 2015-02-15
Genre: Business & Economics
ISBN: 9780160927430

Reports on the state of the United States economy and the Federal budget.

Options for Reducing the Deficit

Options for Reducing the Deficit
Author: Congress, Congressional Budget Office
Publisher: Government Printing Office
Total Pages: 320
Release: 2016
Genre: Business & Economics
ISBN: 9780160936043

This volume presents 115 options that would decrease federal spending or increase federal revenues over the next decade. The federal budget deficit in fiscal year (FY) 2016 totaled $587 billion or 3.2 percent (%) of gross domestic product (GDP), up 2.5 percent (%) in year 2015. The options cover many areas ranging from defense to energy, Social Security and provisions of the tax code. This edition reports the estimated budgetary effects of various options and highlights some of the advantages and disadvantages of those options. Students pursuing research for economic coursework in high school, community college, and university levels may be interested in this vision presented by the Congressional Budget Office, Additionally, economists, federal budget analysts, political science scholars, financial planners, and lawmakers may be interested in this official resource. Related products: Other products produced by the U.S. Congressional Budget Office (CBO) are available here: https: //bookstore.gpo.gov/agency/237Economic Policy resources collection can be found here: https: //bookstore.gpo.gov/catalog/budget-economy/economic-policyEconomic Development publications are available here: https: //bookstore.gpo.gov/catalog/budget-economy/economic-development

The Congressional Budget Office

The Congressional Budget Office
Author: Philip G. Joyce
Publisher: Georgetown University Press
Total Pages: 266
Release: 2011-04-18
Genre: Political Science
ISBN: 1589017587

Created in 1974, the U.S. Congressional Budget Office (CBO) has become one of the most influential forces in national policymaking. A critical component of our system of checks and balances, the CBO has given Congress the analytical capacity to challenge the president on budget issues while it protects the public interest, providing honest numbers about Congress's own budget proposals. The book discusses the CBO’s role in larger budget policy and the more narrow "scoring" of individual legislation, such as its role in the 2009–2010 Obama health care reform. It also describes how the first director, Alice Rivlin, and seven successors managed to create and sustain a nonpartisan, highly credible agency in the middle of one of the most partisan institutions imaginable. The Congressional Budget Office: Honest Numbers, Power, and Policy draws on interviews with high-level participants in the budget debates of the last 35 years to tell the story of the CBO. A combination of political history, economic history, and organizational development, The Congressional Budget Office offers an important, first book-length history of this influential agency.

Research and Development in the Pharmaceutical Industry (A CBO Study)

Research and Development in the Pharmaceutical Industry (A CBO Study)
Author: Congressional Budget Office
Publisher: Lulu.com
Total Pages: 65
Release: 2013-06-09
Genre: Science
ISBN: 1304121445

Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...